



CORRECTION

# Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler<sup>®</sup> to Budesonide/Formoterol Easyhaler<sup>®</sup>

Jörgen Syk · Ines Vinge · Mikael Sörberg · Mikko Vahteristo ·

Paula Ryttilä 

Received: February 22, 2019 / Published online: June 9, 2019  
© The Author(s) 2019

Correction to: Adv Ther

<https://doi.org/10.1007/s12325-019-00940-7>

Unfortunately, the mean difference in change from baseline ACT was incorrectly reported in the abstract as 19.0 vs. 20.8 instead of **18.9 vs. 20.7**

The original version of this article was revised.

**Open Access.** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

---

The original article can be found online at <https://doi.org/10.1007/s12325-019-00940-7>.

---

J. Syk  
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

J. Syk  
Academic Primary Health Care Centre, Stockholm, Sweden

J. Syk  
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden

I. Vinge  
Asthma-Allergy-Lung Department, Lidingö Hospital, Lidingö, Sweden

M. Sörberg  
Orion Pharma, Danderyd, Sweden

M. Vahteristo  
Orion Corporation, Orion Pharma, Kuopio, Finland

P. Ryttilä (✉)  
Orion Corporation, Orion Pharma, Espoo, Finland  
e-mail: paula.rytila@orionpharma.com